Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 34

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 34
---
valuation of the NIS, or that the timing of
such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and
our dollar-denominated results of operations would be adversely affected. Given our general lack of currency hedging arrangements to
protect us from fluctuations in the exchange rates of the NIS and other foreign currencies in relation to the U.S. dollar (and/or from
inflation of such foreign currencies), we may be exposed to material adverse effects from such movements. Our exchange rate exposure
may change over time as our business evolves and could result in increased costs or reduced revenue and could affect our actual cash
flow. Changes in the relative values of currencies occur regularly and, in some instances, may have a significant impact on our operating
results. The rate of inflation in Israel or in currency exchange rates may materially change and we might not be able to effectively
mitigate these risks.

The outcome of any future claims and litigation could have a material adverse impact on our business, financial condition and results of operations.

We may, from time to time,
be party to litigation in the normal course of business, including class action lawsuits. Due to the inherent uncertainties of litigation,
the final outcome of these lawsuits may differ substantially from our expectations and we may not be able to determine the amount of
any potential losses we may incur. In the event we are required or determine to pay amounts in connection with any such lawsuits, such
amounts could be significant and could have a material adverse impact on our liquidity, business, financial condition and results of
operations.

<div align='center'>24</div>

Certain of our directors, director nominees and/or officers may have interests that compete with ours and our shareholders.

Certain of our directors
currently own, operate and manage other entities, which may have similar or different objectives than ours. Such activities could detract
from the time these people have to allocate to our affairs. The terms of such agreements may not be as favorable to us as those that
could be obtained from a third party. Moreover, certain of our directors and officers are affiliated with our current shareholders, and
may have different interests than other shareholders. For additional information regarding related party transactions and potential conflicts
of interest, see “Certain Relationships and Related Party Transactions.” Under the Israeli Companies Law, 5759-1999, or the
Companies Law, office holders must promptly disclose to us any direct or indirect personal interest that he or she may have and